Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Reata Pharmaceuticals
Plano (formerly Irving), Texas, United States
- Ownership
- Public · RETA
- Employees
- ~100
- Development stage
- Other
01
Overview
Reata received FDA approval for Skyclarys (omaveloxolone) in March 2023 for treating Friedreich's ataxia in patients 16 years and older, marking its first approved drug in its 21-year history. The company was acquired by Biogen in September 2023 for approximately $7.3 billion.
- Therapeutic areas
- OncologyRare DiseasesImmunologyRheumatologyNeurologyCardiovascularNephrology
- Modalities
- Small moleculessynthetic triterpenoids
- Industry
- Biotech
02
Partnerships
Previously partnered with AbbVie (reacquired rights)Kyowa Kirin Co., Ltd. (for certain Asian markets for bardoxolone)
Beyond the preview
Go deeper on Reata Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reata Pharmaceuticals.